LAUSR

Abstract Chronic and complex ulcers of the lower limbs constitute a common, persistent, and clinically significant complication, particularly in patients with diabetes, peripheral vascular disease, and other dermatological conditions. These lesions are characterized by impaired healing, high recurrence rates, and a substantial risk of infection, amputation, and functional decline, thereby posing a considerable burden on both patients and healthcare systems. In response to this unresolved clinical need, recombinant human epidermal growth factor (rhEGF) has emerged as an innovative and effective therapeutic strategy. By stimulating cell proliferation, angiogenesis, and tissue regeneration, rhEGF reactivates essential biological processes that are typically impaired in such lesions, thereby promoting accelerated and functional wound healing. Additionally, its anti-inflammatory and antioxidant properties contribute to reducing associated complications, such as infection. Accumulated scientific evidence over recent years has strengthened the support for its clinical use, with multiple studies—including controlled trials, retrospective analyses, and systematic reviews—demonstrating consistent outcomes across various clinical settings. In practice, rhEGF has been established as a safe and effective therapeutic tool with the potential to transform the conventional management of chronic and complex ulcers, improving clinical outcomes and enhancing patients’ quality of life.